Investor Relations

Stock Quote - Ticker Tape

 

Annual Meeting

  o Directions to CEL-SCI's Annual Meeting  
       

SEC Filings

  o View CEL-SCI's SEC Filings  
       

CEL-SCI Presentations & Interviews

  February 23, 2016
Interview with Geert Kersten at the Source Capital 2016 Disruptive Growth & Healthcare Conference

 
  February 17, 2016
NEW CLIP Geert Kersten as a featured guest on Fox Business' Making Money with Charles Payne

 
  February 9, 2016
NEW PRESENTATION Geert Kersten at the 18th Annual BIO CEO & Investor Conference

 
  January 2016
NEW INTERVIEW Interview with Dr. Eyal Talor, Chief Scientific Officer

 
  January 2016
Geert Kersten at the Noble Financial Capital Markets' 12th Annual Investor Conference

 

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o All Press Releases  
 
  JUNE 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in May for Its Phase 3 Head and Neck Cancer Trial
  MAY 24, 2016
NEW STORY CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering
  MAY 10, 2016
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results
  MAY 2, 2016
NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in April for Its Phase 3 Head and Neck Cancer Trial
  APRIL 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in March for Its Phase 3 Head and Neck Cancer Trial
  MARCH 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in February for Its Phase 3 Head and Neck Cancer Trial
  FEBRUARY 9, 2016
NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results
  FEBRUARY 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial
  JANUARY 8, 2016
NEW STORY CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum For 2016
  JANUARY 5, 2016
NEW STORY CEL-SCI Reports Record Year for Patient Enrollment With 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial
  DECEMBER 11, 2015
NEW STORY CEL-SCI Reports Fiscal 2015 Financial Results and Clinical & Corporate Developments
  NOVEMBER 17, 2015
CEL-SCI Is Granted a New European Patent on Its Phase 3 Investigational Cancer Immunotherapy Multikine
  NOVEMBER 4, 2015
CEL-SCI's Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health
  OCTOBER 28, 2015
CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $11.5 Million
  OCTOBER 14, 2015
CEL-SCI to Receive Up to $5,000,000 in Litigation Funding to Support Its Arbitration Suit Against Former CRO
  OCTOBER 5, 2015
Ergomed Increases Its Co-Development Contribution Up To $12,000,000 In CEL-SCI's Phase 3 Head and Neck Cancer Trial

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com